#1 HbA1c
Metformin Therapies → HbA1c
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 86
- consistent
Glycemic Control has evidence across 10 diabetes-related interventions, with strongest support for Metformin Therapies, GLP-1 Receptor Agonists and Diabetes Self-Management Education and Support (DSMES) Programs.
Evidence Intelligence™
Every evidence topic is generated from structured relationships across diabetes research, including topics, interventions, outcomes, and individual studies.
| Rank | Intervention group | Outcome group | EvidenceScore™ | ImpactScore™ | Consistency | Studies | Effectiveness | Action |
|---|---|---|---|---|---|---|---|---|
| #1 | Metformin Therapies | HbA1c | 88/100Strong | 83/100Positive | 86/100consistent | 8 | moderate_positive | Explore evidence |
| #2 | GLP-1 Receptor Agonists | HbA1c | 87/100Strong | 93/100Very Positive | 93/100consistent | 27 | strong_positive | Explore evidence |
| #3 | Diabetes Self-Management Education and Support (DSMES) Programs | Fasting Glucose | 86/100Strong | 81/100Positive | 57/100generally_consistent | 8 | moderate_positive | Explore evidence |
| #4 | Insulin Delivery Systems | CGM Time in Range | 86/100Strong | 72/100Positive | 73/100generally_consistent | 17 | moderate_positive | Explore evidence |
| #5 | Diabetes Self-Management Education and Support (DSMES) Programs | HbA1c | 86/100Strong | 71/100Positive | 68/100generally_consistent | 30 | moderate_positive | Explore evidence |
| #6 | Probiotics and Synbiotics | Fasting Glucose | 85/100Strong | 82/100Positive | 64/100generally_consistent | 11 | moderate_positive | Explore evidence |
| #7 | Probiotics and Synbiotics | HbA1c | 84/100Strong | 88/100Very Positive | 100/100consistent | 12 | strong_positive | Explore evidence |
| #8 | Insulin Delivery Systems | HbA1c | 84/100Strong | 89/100Very Positive | 85/100consistent | 13 | strong_positive | Explore evidence |
| #9 | DPP-4 Inhibitors | CGM Time in Range | 83/100Strong | 75/100Positive | 35/100mixed | 5 | moderate_positive | Explore evidence |
| #10 | GLP-1 Receptor Agonists | Fasting Glucose | 83/100Strong | 69/100Positive | 63/100generally_consistent | 8 | moderate_positive | Explore evidence |
Metformin Therapies → HbA1c
GLP-1 Receptor Agonists → HbA1c
Diabetes Self-Management Education and Support (DSMES) Programs → Fasting Glucose
Insulin Delivery Systems → CGM Time in Range
Diabetes Self-Management Education and Support (DSMES) Programs → HbA1c
Probiotics and Synbiotics → Fasting Glucose
Probiotics and Synbiotics → HbA1c
Insulin Delivery Systems → HbA1c
DPP-4 Inhibitors → CGM Time in Range
GLP-1 Receptor Agonists → Fasting Glucose
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Hybrid closed-loop system, Semaglutide, and Tirzepatide have the strongest available evidence signals for Glycemic Control.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 87.3 | strong positive | ConsistencyScore™ Consistent | 13 studies
Tirzepatide
EvidenceScore™ Strong | EvidenceScore™ 84.6 | strong positive | ConsistencyScore™ Consistent | 9 studies
Hybrid closed-loop system
EvidenceScore™ Strong | EvidenceScore™ 81.0 | strong positive | ConsistencyScore™ Consistent | 8 studies
Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.
Applicability
Population details were available for 1 of 29 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....
Hybrid closed-loop system, Insulin therapy, and Semaglutide are among the most studied areas in relation to Glycemic Control.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 87.3 | strong positive | ConsistencyScore™ Consistent | 15 studies
Hybrid closed-loop system
EvidenceScore™ Strong | EvidenceScore™ 81.0 | strong positive | ConsistencyScore™ Consistent | 10 studies
Insulin therapy
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 6 studies
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Results are mixed or unclear for Acarbose, Behavioral counseling, and Bilberry extract in relation to Glycemic Control.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Continuous glucose monitoring
EvidenceScore™ Strong | EvidenceScore™ 78.6 | weak negative | ConsistencyScore™ Mixed | 3 studies
Dipeptidyl peptidase-4 inhibitors
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Mixed | 2 studies
DSMES
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Mixed | 2 studies
Why this answer: This answer is cautious because the available studies report mixed findings.
Applicability
Population details were available for 1 of 48 supporting studies: Adults with poorly controlled type 2 diabetes identified through a commercial insurer.
Acarbose need more research in relation to Glycemic Control.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Acarbose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Metformin and Semaglutide have available evidence for Glycemic Control, but the comparison requires review of the underlying studies.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 87.3 | strong positive | ConsistencyScore™ Consistent | 13 studies
Metformin
EvidenceScore™ Strong | EvidenceScore™ 85.4 | moderate positive | ConsistencyScore™ Consistent | 7 studies
Why this answer: This answer is based on 18 supporting studies with consistent results and a positive effect signal.
Limitations
Intervention categories most commonly studied for glycemic control outcomes.
Evidence related to diabetes self-management education and support programs in diabetes studies.
Evidence related to GLP-1 receptor agonist therapies in diabetes studies.
Evidence related to insulin therapies in diabetes studies.
Evidence related to probiotic and synbiotic interventions in diabetes studies.
Evidence related to metformin therapies in diabetes studies.
Evidence related to DPP-4 inhibitor therapies in diabetes studies.
Each bubble represents an evidence relationship. Position shows effectiveness and EvidenceScoreâ„¢; size reflects study volume.
Evidence Workspace
Save evidence topics and organize the research that matters to you.